Companies › Curasight
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 64Cu-DOTA-AE105 uPAR-targeting PET imaging agent; copper-64 labeled peptide for PET imaging of uPAR-expres | PLAUR | Phase 2 | Prostate Cancer | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06474806 | 64Cu-DOTA-AE105 | Phase 2 | Prostate Cancer | Oncology | Jan 2027 |
Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.